Notable trends in the market for Erectile Dysfunction (ED) management devices
Marketstrat's research suggests that the market for ED devices will grow at a modest rate, restrained by the more popular medical therapy; another major restraint is patients’ reluctance to seek help.
Primary growth drivers: Rising rates of diabetes and neurological disorders that cause ED; increasing number of men who fail to respond well to medical therapy; education and awareness of ED and treatment options; availability of reimbursement from governmental and private insurance; effective alternative to pills that is preferred by some men.
The market is dominated by 2 companies - AMS and Coloplast, makers of implantable devices.
Greatest market opportunities: In Asia and Latin America for implantable devices. Improved education, access to trained physicians and reimbursement for surgery will be required to tap into these markets
Most notable trends: Market for ED devices will grow at a modest rate, restrained by the more popular medical therapy; another major restraint is patients’ reluctance to seek help.
Primary growth drivers: Rising rates of diabetes and neurological disorders that cause ED; increasing number of men who fail to respond well to medical therapy; education and awareness of ED and treatment options; availability of reimbursement from governmental and private insurance; effective alternative to pills that is preferred by some men
The market is dominated by 2 companies - AMS and Coloplast, makers of implantable devices.
Click here for more details on this report
Greatest market opportunities: In Asia and Latin America for implantable devices. Improved education, access to trained physicians and reimbursement for surgery will be required to tap into these markets
Demand for ED treatment devices will show a steady increase due to:
a) Rising ED rates in association with increasing rates of diabetes and neurological disorders like Parkinson’s disease. Aging populations will add to this trend.
b) Growth will be restrained due to competition from drugs; only patients who are not responsive to medical therapy are referred for devices.
c) Inflatable implants will continue to be the most successful category. Vacuum pumps are expected to gain popularity as supplemental devices.
d) The US and Europe will continue to be the largest geographic markets. However, the market in Asia and Latin America is vastly underpenetrated. Opportunities in these geographic segments are greatest for the malleable prostheses and vacuum pump.
e) Competition in the ED device market involves just two companies, AMS and Coloplast. These companies will enjoy being the sole providers of implantable prostheses for the foreseeable future.
f) There is a push towards the use of implants as the first line of intervention for ED, with the justification that close to half of the patient population, who suffer from ED due to diabetes or prostate surgery, are not responsive to medication. An expert at Cornell University also argues that men who are initially treatable with oral medications and injections eventually lose their sensitivity, whereas implants offer a reliable, long term solution. Contradicting this is evidence that points to effectiveness of medical therapy for 90 percent of men who undergo non-nerve sparing radical prostatectomy. Penile injection therapy and penile suppositories are less popular; most patients drop out after one or two years. Further clinical evidence will be required for a move away from medical therapy.
g) Medtronic Inc. is exploring a way to enter the ED market with a stent device that will offer a solution to men whose ED is due to circulatory problems.
Click here for more details on this report
Competition
AMS and Coloplast dominate the market with their highly successful and well established implantable prostheses for ED. Other companies offer vacuum pumps/ erection devices, some of which are approved by regulatory agencies such as the FDA.
Comments